Kahn Brothers’ Top Stock Picks For Q3

Irving and Thomas Kahn are value investors who have been running their investment firm since 1978. Irving Kahn was one of legendary value investor Benjamin Graham’s students, and the firm’s emphasis on a stock’s pricing relative to its book value and historical earnings is much in line with that tradition. In early November Kahn Brothers filed its 13F for the third quarter of 2012, which discloses many of its long equity positions as of the end of September. Read on for our quick take on its top five holdings and compare their picks to previous filings.

Irving Kahn

The fund’s top pick was pharmaceutical manufacturer Pfizer Inc. (NYSE:PFE), with Kahn Brothers reporting a position of 2.5 million shares- essentially unchanged from three months earlier. The $184 billion market cap giant reported earnings growth of 25% in its most recent quarterly report compared to the same period in 2011 despite somewhat lower revenue. It trades at 18 times trailing earnings, but an optimistic analyst group projects continued strong growth that implies a forward P/E of only 11. With a 3.5% dividend yield as well, Pfizer’s got our attention; however, we’d need to do due diligence on that projected path to such an attractive P/E multiple. Billionaire Ken Fisher’s Fisher Asset Management has been another large investor in Pfizer.

New York Community Bancorp, Inc. (NYSE:NYB) was another of Kahn Brothers’ favorite stocks, though as with Pfizer the fund’s position was more or less unchanged at 3.6 million shares. The retail bank holding company trades at somewhat higher P/E and P/B multiples than many large banks- it is priced at 1.1 times the book value of its equity, and 12 times trailing earnings- but on an absolute basis New York Community Bancorp does not look particularly overpriced. The stock also offers a 7.2% dividend yield, having paid a 25 cent per share dividend every quarter since April 2004. Value investors should look at other banks, but income investors should take it into consideration.

Kahn Brothers’ position in Merck & Co., Inc. (NYSE:MRK) was also kept steady at 1.1 million shares. Like Pfizer, Merck is not a particularly good value stock when looking at trailing earnings- the P/E multiple is 21- but if Wall Street analysts are right then the company is in for some very good quarters that will bring its earnings up. That P/E becomes 12 on the basis of forward estimates. Merck’s dividend yield is also good, at 4.5%. As with Pfizer, we like that pricing as long as the company can deliver on those earnings targets- and would like to check the company out more closely.

The firm did slightly increase its stake in, of all things, The New York Times Company (NYSE:NYT), with the 4.7 million shares in its portfolio at the end of September being just a bit higher than the 4.6 million that it had owned three months earlier. The New York Times experienced a 16% decline in revenue in the third quarter of the year versus Q3 2011, which contributed to an 86% decrease in earnings over the same period. At 17 times consensus earnings for 2013- a figure which reflects a dramatic improvement in its business- we don’t think that investors should be buying.

Citigroup Inc. (NYSE:C) gave Kahn Brothers some exposure to the big banks in the second quarter, when the firm had bought the stock heavily, and it broke into the top five holdings in the 13F portfolio by the end of the third quarter. The megabank is getting a new CEO with the departure of Vikram Pandit, and is up 33% year to date. This has brought it to a multiple of 8 times expected earnings for next year, which we’d normally consider to be value territory, and it also trades at a steep discount to book value. We looked at Citi recently and decided that investors could buy it, JPMorgan Chase, or Wells Fargo depending on how much they valued low multiples versus safety and stability. Read our recent analysis of Citigroup.

Biotech Insider Alert - $6 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The Most Wanted Drug Lords

The Oldest Money Managers

The Greatest Directors in the World

Largest Animals in the World

World’s Most Expensive Desserts

Best Selling Comic Books of All Time

A-list Actors who Sabotaged Their Career

Rappers With a College Degree

The Best Jazz Albums of all Time

The Most Influential Jazz Musicians

The World’s Most Famous Photographers

The Best Oscar-Winning Songs

Most Influential Choreographers Ever

Most Expensive Department Stores in the World

The Most Expensive Stolen Paintings in the World

The World’s Most Expensive Teas

Top Oscar Record Holders

The Most Expensive Flowers in the World

Countries With a Booming Film Industry

Most Expensive Cupcakes in the World

Uncommon European Escapes

The Most Stolen Artists in History

Best Travel Destinations in Australia

World’s Most Expensive Musical Instruments

World’s Most Famous Animals

Most Expensive Cakes in the World

Most Expensive Kosher Champagne in the World

Most Expensive Kosher Wine in the World

The Most Surprisingly Dark Fairy Tales

Most Popular Travel Destinations in Asia

The 10 Most Expensive Dresses Ever Worn to the Oscars

World’s Most Visited Art Museums

Best Countries for Photographers to Work in

Best Paid Jobs in the Film Industry

The Most Renowned Recovered Paintings Ever

Child Stars That Turned out Just Fine

Books That Were Banned in the Past Century

World’s Richest Dancers

Best Remedies against Bad Breath

Foods That Improve Your Skin Texture

Best-Selling Children’s Books of all Time

Foods That Boost Your Libido

Best-Selling Books of all Time

The Most Expensive Academy Awards Jewelry in History

Most Expensive Japanese Restaurant In New York City

The Best B-Boy Movies

Most Awesome Hip Hop Documentaries

Foods That Stain Your Teeth

Richest Doctors in the World

The Best Movie Sountracks Ever

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!